ULTIMA-CJC NO DAC 5MG - Advanced GHRH Peptide Support

Optimize your body's regenerative potential with ULTIMA-CJC NO DAC. This precision-formulated peptide is designed for those seeking to support growth hormone secretion and cellular repair through high-quality, laboratory-tested peptide technology.

Specifications

Description/How it works

CJC-1295 (No DAC) is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). Composed of 30 amino acids, this peptide is engineered to increase growth hormone secretion and Insulin-like Growth Factor 1 (IGF-1) levels. Unlike some other peptides, it is designed to work effectively without adversely affecting the natural pulsatility of GH secretion.

This specific formulation is highly regarded for its ability to support protein synthesis, which is essential for muscle growth, improved bone density, and enhanced collagen production. It is also an excellent tool for promoting cellular repair and rejuvenation. For professionals looking for synergy, this peptide is frequently paired with Ipamorelin to provide enhanced results without the excessive appetite stimulation or cortisol increases seen in other classes of peptides.

While the "No DAC" version offers a shorter half-life compared to DAC-modified versions, it provides a more natural-feeling response, avoiding the potential for decreased GH pulse amplitude associated with long-acting complexes.

FAQ

What is the difference between CJC-1295 and CJC-1295 with DAC?
CJC-1295 (No DAC) features a shorter half-life, whereas the DAC (Drug Affinity Complex) version features an enhanced half-life of up to 8 days due to its binding to albumin. However, the DAC version may lead to decreased GH pulse amplitude and tissue stimulation.

Are there any side effects?
Common side effects associated with CJC-1295 may include injection site reactions, headaches, diarrhea, vasodilation, nausea, or abdominal pain. Regular adherence to established protocols is essential for safety.

What is a "hormone holiday"?
A hormone holiday is a period of rest from long-acting molecules intended to allow the pituitary gland to recover. This practice may help mitigate the risk of GH resistance, which can be characterized by decreased receptor density or antibody formation.